Rentokil Stock Edges Higher, But North America Is Still The Test Investors Cannot Ignore
Rentokil Initial shares rose 0.63% to 476.90p in London on Thursday, partially rebounding after declines earlier in the week. First-quarter revenue increased 4.3% to $1.68 billion, with North America organic growth at 3.9%. U.S. rival Rollins reported 6.6% organic growth for the same period. CEO Mike Duffy cited “continued momentum in North America” despite ongoing market pressure.